Table 2.

Effect of diabetes status at baseline on the endpoints in the placebo group.

	Events	Unadjusteda		Adjusted for multiple variablesb
Subgroup	% (n/N)	HR (95% CI)	p-value	HR (95% CI)	p-value
Composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization
No diabetes mellitus	8.8 (197 out of 2,245)
Type 2 diabetes mellitus	13.0 (67 out of 515)	1.54 (1.16–2.03)	<0.01	1.52 (1.15–2.01)	<0.01
Composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke
No diabetes mellitus	5.2 (116 out of 2,245)
Type 2 diabetes mellitus	8.0 (41 out of 515)	1.57 (1.10–2.24)	0.01	1.55 (1.08–2.21)	0.02
Spontaneous myocardial infarction
No diabetes mellitus	3.9 (87 out of 2,245)
Type 2 diabetes mellitus	5.6 (29 out of 515)	1.47 (0.96–2.24)	0.07	1.45 (0.95–2.20)	0.09
Ischemia-driven coronary revascularization
No diabetes mellitus	5.8 (130 out of 2,245)
Type 2 diabetes mellitus	9.1 (47 out of 515)	1.63 (1.17–2.28)	<0.01	1.63 (1.16–2.27)	<0.01
Cardiovascular death
No diabetes mellitus	0.8 (17 out of 2,245)
Type 2 diabetes mellitus	1.6 (8 out of 515)	2.03 (0.88–4.71)	0.10	2.06 (0.89–4.78)	0.09
Ischemic stroke
No diabetes mellitus	0.8 (17 out of 2,245)
Type 2 diabetes mellitus	1.4 (7 out of 515)	1.78 (0.74–4.30)	0.20	1.74 (0.72–4.21)	0.22

Analysis compared diabetes vs. no diabetes.

^a Hazard ratios adjusted for treatment were only marginally different compared with unadjusted hazard ratios.

^b Adjusted for the baseline characteristics from Table 1 that were independent predictors of the primary endpoint: age >70 years, current smoker, a history of both coronary artery bypass grafting and percutaneous coronary intervention, a combination of oral anticoagulants and dual antiplatelet therapy, and no statin use (19).